STOCK TITAN

[Form 4] THERMO FISHER SCIENTIFIC INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Dion J. Weisler, a director of Thermo Fisher Scientific, reported a Section 16 transaction dated 09/27/2025. The filing shows Phantom Stock Units were acquired under the company's Deferred Compensation Plan for Directors and are convertible 1-for-1 into common stock. The report states units were credited at $464.24 per unit and lists 80.78 as the number associated with the reported acquisition and 2,573.95 as the amount of common stock beneficially owned following the transaction. The units are distributable as stock upon cessation of director service or a change of control. The form was signed by an attorney-in-fact on 09/30/2025.

Dion J. Weisler, un direttore di Thermo Fisher Scientific, ha riportato una transazione della Sezione 16 datata 27/09/2025. Il deposito indica che Unità fantasma sono state acquisite ai sensi del Piano di compensazione differita per i direttori e sono convertibili 1-1 in azioni ordinarie. Il rapporto specifica che le unità sono state accredite a 464,24 USD per unità e indica 80,78 come numero associato all'acquisizione riportata e 2.573,95 come l'ammontare di azioni ordinarie detenute beneficiariamente dopo la transazione. Le unità possono essere distribuite come azioni al cessare della funzione di direttore o al cambiamento di controllo. Il modulo è stato firmato da un procuratore facente funzione il 30/09/2025.

Dion J. Weisler, un director de Thermo Fisher Scientific, informó una operación de la Sección 16 con fecha 27/09/2025. La presentación muestra que Unidades de Acciones Fantasma se adquirieron bajo el Plan de Compensación Diferida para Directores y son convertibles 1-1 en acciones ordinarias. El informe indica que las unidades fueron acreditadas a 464,24 USD por unidad y señala 80,78 como el número asociado a la adquisición reportada y 2.573,95 como el monto de las acciones comunes beneficiosas tras la transacción. Las unidades son distribuibles como acciones al cese de la función de director o ante un cambio de control. El formulario fue firmado por un apoderado en fecha 30/09/2025.

Thermo Fisher Scientific의 이사인 Dion J. Weisler는 2025-09-27에 해당하는 Section 16 거래를 보고했습니다. 신고서에 따르면 팬텀 주식 단위가 회사의 이사들을 위한 연금 보상 계획에 따라 취득되었으며 주당 1대1로 일반 주식으로 전환 가능합니다. 보고서는 단위가 단위당 464.24달러로 적립되었고 80.78을 보고된 취득과 연관된 번호로, 2,573.95를 거래 후 실제 소유 일반 주식 수로 기재한다고 합니다. 이 단위는 이사 직무를 중단하거나 지배권 변경 시 주식으로 분배될 수 있습니다. 양식은 2025-09-30에 대리인이 서명했습니다.

Dion J. Weisler, administrateur chez Thermo Fisher Scientific, a signalé une transaction selon la Section 16 datée du 27 septembre 2025. Le dépôt indique que des unités d’actions fantômes ont été acquises dans le cadre du Plan de compensation différée pour les administrateurs et qu’elles sont convertibles 1 pour 1 en actions ordinaires. Le rapport précise que les unités ont été créditées à 464,24 USD par unité et mentionne 80,78 comme le numéro associé à l’acquisition rapportée et 2 573,95 comme le montant des actions ordinaires détenues après la transaction. Les unités peuvent être distribuées en actions lors de la cessation de fonction d’administrateur ou lors d’un changement de contrôle. Le formulaire a été signé par un mandataire le 30 septembre 2025.

Dion J. Weisler, ein Vorstand von Thermo Fisher Scientific, meldete eine Transaktion gemäß Section 16 vom 27.09.2025. Die Einreichung zeigt, dass Phantom-Stock-Einheiten im Rahmen des Deferred Compensation Plan for Directors des Unternehmens erworben wurden und 1-zu-1 in Stammaktien umwandelbar sind. Der Bericht gibt an, dass die Einheiten mit 464,24 USD pro Einheit gutgeschrieben wurden und führt 80,78 als die mit dem Erwerb verknüpfte Nummer und 2.573,95 als den Betrag der nach der Transaktion tatsächlich gehaltenen Stammaktien auf. Die Einheiten können bei Beendigung der Direktorentätigkeit oder bei einer Veränderten der Kontrolle als Aktien ausgeschüttet werden. Das Formular wurde am 30.09.2025 von einem Bevollmächtigten unterzeichnet.

دِيون ج. وايسلر، مدير في شركة Thermo Fisher Scientific، أبلغ عن معاملة وفق القسم 16 بتاريخ 27/09/2025. يبيّن الملف أن وحدات الأسهم الوهمية تم الحصول عليها بموجب خطة التعويض المؤجل للمديرين وهي قابلة للتحويل 1-إلى-1 إلى أسهم عادية. يذكر التقرير أن الوحدات تم إئتمانها بسعر 464.24 دولارًا للوحدة ويذكر 80.78 كرقم مرتبط بالاستحواذ المبلغ و2,573.95 كمقدار الأسهم العادية التي يمتلكها المستفيد بعد الصفقة. يمكن توزيع الوحدات كسهم عند إنهاء خدمة المدير أو عند حدوث تغيير في السيطرة. تم توقيع النموذج من قبل وكيل قانوني في 30/09/2025.

Dion J. Weisler, Thermo Fisher Scientific 的董事,报告了日期为 2025-09-27 的第 16 条交易。 备案显示在公司的董事延迟补偿计划下取得的 虚拟股票单位,可 1:1 转换为普通股。报告称单位按每单位 464.24 美元 入账,并列出 80.78作为与此次收购相关的编号,以及 2,573.95 作为交易后实际拥有的普通股数量。这些单位在董事停止任职或发生控制权变更时可分配为股票。该表格于 2025-09-30 由代理律师签字。

Positive
  • Units are convertible 1-for-1 into common stock, providing straightforward equity linkage
  • Transaction was executed under the Deferred Compensation Plan, showing standard director compensation governance and disclosure
Negative
  • None.

Insights

TL;DR: Routine director deferred-compensation credit; convertible units increase deferred equity exposure but are non-cash until distribution.

The Form 4 documents a standard crediting of phantom stock units under the issuer's Director Deferred Compensation Plan, recorded at a closing price basis of $464.24 per unit. The instrument is convertible 1-for-1 into common shares and is distributable only upon service termination or change of control, so the transaction represents deferred equity compensation rather than an immediate equity sale or purchase. This is a typical Section 16 disclosure for directors and does not reflect open-market trading activity.

TL;DR: Disclosure aligns with standard director compensation practices; materiality to investors is low absent other changes.

The filing specifies that director retainers are deferred quarterly into stock units and credited as of the quarter end. The units’ 1-for-1 convertibility and distribution triggers (cessation of service or change of control) are explicitly stated, indicating standard vesting/distribution mechanics. The transaction increases disclosed beneficial ownership to 2,573.95 shares but reflects plan mechanics rather than a strategic ownership shift.

Dion J. Weisler, un direttore di Thermo Fisher Scientific, ha riportato una transazione della Sezione 16 datata 27/09/2025. Il deposito indica che Unità fantasma sono state acquisite ai sensi del Piano di compensazione differita per i direttori e sono convertibili 1-1 in azioni ordinarie. Il rapporto specifica che le unità sono state accredite a 464,24 USD per unità e indica 80,78 come numero associato all'acquisizione riportata e 2.573,95 come l'ammontare di azioni ordinarie detenute beneficiariamente dopo la transazione. Le unità possono essere distribuite come azioni al cessare della funzione di direttore o al cambiamento di controllo. Il modulo è stato firmato da un procuratore facente funzione il 30/09/2025.

Dion J. Weisler, un director de Thermo Fisher Scientific, informó una operación de la Sección 16 con fecha 27/09/2025. La presentación muestra que Unidades de Acciones Fantasma se adquirieron bajo el Plan de Compensación Diferida para Directores y son convertibles 1-1 en acciones ordinarias. El informe indica que las unidades fueron acreditadas a 464,24 USD por unidad y señala 80,78 como el número asociado a la adquisición reportada y 2.573,95 como el monto de las acciones comunes beneficiosas tras la transacción. Las unidades son distribuibles como acciones al cese de la función de director o ante un cambio de control. El formulario fue firmado por un apoderado en fecha 30/09/2025.

Thermo Fisher Scientific의 이사인 Dion J. Weisler는 2025-09-27에 해당하는 Section 16 거래를 보고했습니다. 신고서에 따르면 팬텀 주식 단위가 회사의 이사들을 위한 연금 보상 계획에 따라 취득되었으며 주당 1대1로 일반 주식으로 전환 가능합니다. 보고서는 단위가 단위당 464.24달러로 적립되었고 80.78을 보고된 취득과 연관된 번호로, 2,573.95를 거래 후 실제 소유 일반 주식 수로 기재한다고 합니다. 이 단위는 이사 직무를 중단하거나 지배권 변경 시 주식으로 분배될 수 있습니다. 양식은 2025-09-30에 대리인이 서명했습니다.

Dion J. Weisler, administrateur chez Thermo Fisher Scientific, a signalé une transaction selon la Section 16 datée du 27 septembre 2025. Le dépôt indique que des unités d’actions fantômes ont été acquises dans le cadre du Plan de compensation différée pour les administrateurs et qu’elles sont convertibles 1 pour 1 en actions ordinaires. Le rapport précise que les unités ont été créditées à 464,24 USD par unité et mentionne 80,78 comme le numéro associé à l’acquisition rapportée et 2 573,95 comme le montant des actions ordinaires détenues après la transaction. Les unités peuvent être distribuées en actions lors de la cessation de fonction d’administrateur ou lors d’un changement de contrôle. Le formulaire a été signé par un mandataire le 30 septembre 2025.

Dion J. Weisler, ein Vorstand von Thermo Fisher Scientific, meldete eine Transaktion gemäß Section 16 vom 27.09.2025. Die Einreichung zeigt, dass Phantom-Stock-Einheiten im Rahmen des Deferred Compensation Plan for Directors des Unternehmens erworben wurden und 1-zu-1 in Stammaktien umwandelbar sind. Der Bericht gibt an, dass die Einheiten mit 464,24 USD pro Einheit gutgeschrieben wurden und führt 80,78 als die mit dem Erwerb verknüpfte Nummer und 2.573,95 als den Betrag der nach der Transaktion tatsächlich gehaltenen Stammaktien auf. Die Einheiten können bei Beendigung der Direktorentätigkeit oder bei einer Veränderten der Kontrolle als Aktien ausgeschüttet werden. Das Formular wurde am 30.09.2025 von einem Bevollmächtigten unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
WEISLER DION J

(Last) (First) (Middle)
168 THIRD AVENUE

(Street)
WALTHAM MA 02451

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock Units (1) 09/27/2025 A 80.78 (2) (2) Common Stock 80.78 (2) 2,573.95 D
Explanation of Responses:
1. Convertible into Common Stock on a 1-for-1 basis.
2. Represents stock units credited to the Reporting Person's account as of September 27, 2025, at a price of $464.24 per unit pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Directors' retainers are deferred quarterly under the Plan as Common Stock units based on the closing price of the stock as of the quarter end. The shares are distributable as stock upon cessation of director service (for any reason) or a change of control.
/s/ Melodie T. Morin, Attorney-in-Fact for Dion J. Weisler 09/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dion J. Weisler report on the Form 4 for TMO?

The Form 4 reports the acquisition of Phantom Stock Units under Thermo Fisher's Director Deferred Compensation Plan dated 09/27/2025, and shows 2,573.95 shares beneficially owned following the transaction.

How many phantom stock units were credited and at what price?

The filing shows an acquisition entry associated with 80.78 (as reported) and states units were credited at $464.24 per unit under the Plan.

Are the credited units convertible to Thermo Fisher common stock (TMO)?

Yes. The filing explicitly states the units are convertible into common stock on a 1-for-1 basis.

When are the deferred units distributable as stock?

The units are distributable as stock upon cessation of director service for any reason or upon a change of control, per the filing.

Was the Form 4 signed and when?

Yes. The Form 4 was signed by an attorney-in-fact on 09/30/2025.
Thermo Fishr Sci

NYSE:TMO

TMO Rankings

TMO Latest News

TMO Latest SEC Filings

TMO Stock Data

183.15B
376.95M
0.16%
91.87%
1.04%
Diagnostics & Research
Measuring & Controlling Devices, Nec
Link
United States
WALTHAM